AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 232 min read$NAMS

NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?

NewAmsterdam Pharma (NASDAQ:NAMS) received EU approval for two cholesterol-lowering drugs, Ubeslo and Evlarco. Menarini holds commercialization rights, with NAMS eligible for royalties. The company reported $678.3M in cash as of June 30, 2026. Clinical trials are ongoing to assess cardiovascular benefits.

Original reporting
insidermonkey.com
Published Sep 23, 2026, 1:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 2:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
NewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties? — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$NAMSBullishHigh
01

Why it matters

The approval unlocks royalty revenue streams and milestone payments, but commercial uptake depends on pricing, reimbursement, and outcomes from the ongoing PREVAIL trial.

02

Market read

Regulatory approval is a primary catalyst for NAMS, likely prompting a short‑term price rally and influencing the broader cholesterol‑drug sector.

03

What to watch

Pending PREVAIL outcomes and launch pricing may delay meaningful cash flow.

Relevance 9/10Novelty 9/10Timing: September 21 approval announced today

Background

NewAmsterdam Pharma (NASDAQ:NAMS) secured EU approval for two obicetrapib‑based products, entering a partnership with Menarini for commercialization.

Company-level read

Ticker impact

$NAMSBullishHigh confidence
Context

EU Commission approved NewAmsterdam's cholesterol drugs, the first global approvals, creating royalty revenue potential.

Expected impact

Potential short-term rally of 5‑10% on approval news, followed by longer-term volatility tied to launch execution.

Evidence & confidence

Approval is a material catalyst for a micro‑cap biotech; peers typically see price spikes on first‑in‑region approvals.

Market effects

Sector

Adds momentum to the cholesterol‑lowering drug segment and may boost related biotech peers.

Regional

Strengthens European pharma pipeline perception, supporting European biotech sentiment.

Global

First global approval could influence global cholesterol‑drug market dynamics.

Counterpoint

What could challenge this read

Royalty tiering and uncertain reimbursement could limit near‑term revenue, tempering upside.

Key entities

  • company
    NewAmsterdam Pharma

    Biotech developer of obicetrapib cholesterol drugs.

  • partner
    Menarini

    European commercial partner holding exclusive rights.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 21
$NAMSMedAI 8/10

NewAmsterdam Pharma Co N.V. (NAMS): Other Events

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. On September 21, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) along with its partner Menarini Group (“Menarini”) announced that the European Commission (“EC”) has granted marketing authorization for Ubeslo ® (obicetrapib 10 mg monotherapy) and Ev

SEC EDGAR 8-K2 min
AUG 5
$NAMSMed

NewAmsterdam Pharma Co N.V. (NAMS): Results of Operations and Financial Condition

NewAmsterdam Pharma Co N.V. (NAMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results – Announced positive CHMP opinion recommending marketing authorization for obicetrapib and obicetrapib/ezetimibe – – PREVAIL interim analysis planned for 4Q2026 with result expected in 1Q20

SEC EDGAR 8-K7 min
JUL 24
$NAMSMed

NewAmsterdam, Menarini Cholesterol Drugs Receive Positive Opinion From CHMP

NewAmsterdam Pharma (NAMS) and Menarini said the EMA CHMP issued a positive opinion for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for adults with primary hypercholesterolemia. CHMP based on Phase 3 BROADWAY, BROOKLYN and TANDEM; LDL-C fell up to 40% with monotherapy and about 50% with the combo vs placebo. European Commission decision expected H2 2026.

rttnews.com3 min
JUL 24
$NAMSMedAI 8/10

Menarini Industrie Farmaceutiche Riunite: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Ob

NewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending EU marketing authorization for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing LDL-C reductions up to 40% and about 50%. The European Commission decision is expected in 2H26.

finanznachrichten.de6 min
JUL 24
$NAMSMedAI 8/10

NewAmsterdam Pharma Company N.V.: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapi

NewAmsterdam Pharma (Nasdaq: NAMS) and Menarini said the EMA CHMP issued a positive opinion recommending marketing authorization in Europe for Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg plus ezetimibe 10 mg) for primary hypercholesterolemia. The recommendation is based on Phase 3 BROADWAY, BROOKLYN, and TANDEM results showing LDL-C reductions up to 40% and about 50%. European Commission decision expected in 2H26.

finanznachrichten.de4 min